Immunohistochemical determination of oestrogen receptor: comparison of different methods of assessment of staining and correlation with clinical outcome of breast cancer patients.
about
American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancerBAG-i expression in human breast cancer: interrelationship between BAG-1 RNA, protein, HSC70 expression and clinico-pathological data.Fractionated evaluation of immunohistochemical hormone receptor expression enhances prognostic prediction in breast cancer patients treated with tamoxifen as adjuvant therapyPrognostic and predictive value of low estrogen receptor expression in breast cancer14-3-3σ induces heat shock protein 70 expression in hepatocellular carcinoma.Significance of immunohistochemistry in breast cancerImmunohistochemical expression of epithelial and stromal immunomodulatory signalling molecules is a prognostic indicator in breast cancer.Trace elements as tumor biomarkers and prognostic factors in breast cancer: a study through energy dispersive x-ray fluorescenceType 10 soluble adenylyl cyclase is overexpressed in prostate carcinoma and controls proliferation of prostate cancer cells14-3-3ε overexpression contributes to epithelial-mesenchymal transition of hepatocellular carcinoma.Dual-color fluorescence in situ hybridization reveals an association of chromosome 8q22 but not 8p21 imbalance with high grade invasive breast carcinoma.Immunohistochemical demonstration of oestrogen and progesterone receptors: correlation of standards achieved on in house tumours with that achieved on external quality assessment material in over 150 laboratories from 26 countries.Frequency of oestrogen and progesterone receptor positivity by immunohistochemical analysis in 7016 breast carcinomas: correlation with patient age, assay sensitivity, threshold value, and mammographic screening.Comparison of core oestrogen receptor (ER) assay with excised tumour: intratumoral distribution of ER in breast carcinomaSignificance of serum microRNA-21 in diagnosis of hepatocellular carcinoma (HCC): clinical analyses of patients and an HCC rat model.Impact of low estrogen/progesterone receptor expression on survival outcomes in breast cancers previously classified as triple negative breast cancersReliability of immunohistochemical demonstration of oestrogen receptors in routine practice: interlaboratory variance in the sensitivity of detection and evaluation of scoring systems.The effect of fixation and processing on the sensitivity of oestrogen receptor assay by immunohistochemistry in breast carcinomaSignificant expression of IGFBP2 in breast cancer compared with benign lesions.Cellular and molecular regulation of the primate endometrium: a perspectiveIncreased expression of 14-3-3β promotes tumor progression and predicts extrahepatic metastasis and worse survival in hepatocellular carcinoma.The reliability of assessment of oestrogen receptor expression on needle core biopsy specimens of invasive carcinomas of the breast.Novel polymorphisms in caspase-8 are associated with breast cancer risk in the California Teachers StudyRelationship of nm23 to proteolytic factors, proliferation and motility in breast cancer tissues and cell lines.Prognostic factors for breast cancer and their use in the clinical setting.Immunohistochemical determination of estrogen and progesterone receptors in breast cancer: relationship with clinicopathologic factors in 302 patients in Ivory CoastTumor markers in breast cancer- European Group on Tumor Markers recommendations.Quantitative analysis of estrogen receptor expression shows SP1 antibody is more sensitive than 1D5.Expression of partitioning defective 3 (Par-3) for predicting extrahepatic metastasis and survival with hepatocellular carcinoma.CGH analysis of ductal carcinoma of the breast with basaloid/myoepithelial cell differentiation.Regulation of aldo-keto-reductase family 1 B10 by 14-3-3ε and their prognostic impact of hepatocellular carcinoma.SGK3 is associated with estrogen receptor expression in breast cancer.Current issues in ER and HER2 testing by IHC in breast cancer.In situ Protein Detection for Companion Diagnostics.Use of NRP1, a novel biomarker, along with VEGF-C, VEGFR-3, CCR7 and SEMA3E, to predict lymph node metastasis in squamous cell carcinoma of the tongue.The effect of prolonged cold ischemia time on estrogen receptor immunohistochemistry in breast cancer.Hormone receptor expression in breast cancer: postanalytical issues.Hormone receptors and Her2 expression in breast cancer in sub-Saharan Africa. A comparative study of biopsies from Ghana and Norway.Discordance between original and central laboratories in ER and HER2 results in a diverse, population-based sample.Tumor heterogeneity and personalized cancer medicine: are we being outnumbered?
P2860
Q30494798-2CC455E0-3EE0-4AC9-9FC1-33076A102E60Q30699989-D07EF76E-4FAD-47F1-9901-202809147A01Q33568902-87683367-0F6E-40C6-B18D-91E6EAEB498EQ33611133-9596ED3B-43C6-4259-B24F-1B34A9C3002FQ33769256-D5F0FDB5-B173-4522-BE32-2CB31A51343BQ34023682-57DAD8CF-8617-4C0F-8DD9-2D3C2DD762BFQ34165529-25594270-76F4-4015-9BFC-A9AA35A92BB1Q34245766-0D3FB989-336E-4521-AF86-BED8D6B491D8Q34318699-23DE596F-47DD-4712-B1B1-64C91E4FF6AAQ34618508-8D5CAF47-39D7-454B-AF50-8C0475E5E8ABQ34923557-8B6B83AC-94A4-422F-868F-03342A062B7DQ35396049-94B365DD-24F7-439F-B98F-786C3C9BE31AQ35396974-C27D18B2-258D-4C2A-A9FA-6E02AF7783E2Q35397963-99F9B876-1F18-4E4B-85F6-9558658F37B8Q35405060-0677DDC7-D337-4DDB-97FC-9CB1EDEA0EFCQ35552416-CF0654FC-5BC1-40FD-BF40-31E6E827966CQ35571861-689B7577-F2BF-4133-8715-F5656428616CQ35586038-EC5E71E4-5A33-41C3-AD90-E5464F37FD1AQ35588467-1AC77B42-718C-4D89-9D25-244355DF02ABQ35598634-261B1037-3F74-4B3E-9B2D-0194202C0FF0Q35679527-228E09D0-A1F5-4219-964B-922B7DB353E9Q35770497-FFA2F14C-7D5C-4F16-8685-9E2561459AB7Q35892049-EB2933FB-9725-44FF-8545-287E07C9E7FDQ36114910-E3317B9F-345F-4149-8D7E-39B43A9128E8Q36118398-5159A21B-005B-4DC3-A208-6764226351BAQ36273328-F345F5A9-754C-425D-8C64-1F4DE20AD7B6Q36299309-4DE5FCEC-3603-45B5-AC05-76BEB63B85A9Q36350762-4904DA50-9C07-45F4-99FA-B7437003DA9CQ36590103-995AA59C-0EE9-4A5C-B2A6-7772C539A22FQ36623521-1C9FE75F-7637-4293-A607-1152BEB3C54BQ36629475-7923475B-6455-4F06-B199-D337CF49AB09Q36934463-EF247170-8D09-4F64-B453-DFA701612ECCQ37147777-D27B47AC-B483-4AFF-8778-90BB5F963787Q37270405-69A1108D-597F-4E6B-AC8F-B5DE742FDF37Q37321171-1C141F41-250F-44B6-810B-C6FCF597D63FQ37436042-8792A3C6-9A01-455A-B60D-C0CB249E7918Q38092775-DD76E379-2ABD-443A-A3B3-D95D8C9D6BB7Q38202689-11AD789A-3A02-40F5-9344-9E39E47CD435Q38377039-363D790B-696A-43DB-96B9-20CAB85B4F5EQ39246718-D600A9FF-E2C8-4500-B000-79A325154E69
P2860
Immunohistochemical determination of oestrogen receptor: comparison of different methods of assessment of staining and correlation with clinical outcome of breast cancer patients.
description
1996 nî lūn-bûn
@nan
1996年の論文
@ja
1996年論文
@yue
1996年論文
@zh-hant
1996年論文
@zh-hk
1996年論文
@zh-mo
1996年論文
@zh-tw
1996年论文
@wuu
1996年论文
@zh
1996年论文
@zh-cn
name
Immunohistochemical determinat ...... ome of breast cancer patients.
@ast
Immunohistochemical determinat ...... ome of breast cancer patients.
@en
type
label
Immunohistochemical determinat ...... ome of breast cancer patients.
@ast
Immunohistochemical determinat ...... ome of breast cancer patients.
@en
prefLabel
Immunohistochemical determinat ...... ome of breast cancer patients.
@ast
Immunohistochemical determinat ...... ome of breast cancer patients.
@en
P2093
P2860
P356
P1476
Immunohistochemical determinat ...... ome of breast cancer patients.
@en
P2093
P2860
P2888
P304
P356
10.1038/BJC.1996.563
P407
P577
1996-11-01T00:00:00Z